0001209191-16-095840.txt : 20160204
0001209191-16-095840.hdr.sgml : 20160204
20160204185122
ACCESSION NUMBER: 0001209191-16-095840
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160202
FILED AS OF DATE: 20160204
DATE AS OF CHANGE: 20160204
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arbuckle Stuart A
CENTRAL INDEX KEY: 0001557290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 161389820
MAIL ADDRESS:
STREET 1: VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-02-02
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001557290
Arbuckle Stuart A
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP\Chief Commercial Officer
Common Stock
2016-02-02
4
A
0
17299
0.01
A
121763
D
Common Stock
2016-02-03
4
S
0
2597
89.92
D
119166
D
Common Stock
2016-02-03
4
S
0
2100
90.98
D
117066
D
Common Stock
2016-02-03
4
S
0
700
91.89
D
116366
D
Common Stock
2016-02-03
4
S
0
645
92.80
D
115721
D
Common Stock
140
I
401(k)
Stock Option (Right to Buy)
91.05
2016-02-02
4
A
0
34482
0.00
A
2026-02-01
Common Stock
34482
34482
D
Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $89.92 (range $89.31 to $90.27).
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $90.98 (range $90.38 to $91.32).
Open market sales reported on this line occurred at a weighted average price of $91.89 (range $91.38 to $92.35).
Open market sales reported on this line occurred at a weighted average price of $92.80 (range $92.40 to $93.03).
The option vests in 16 quarterly installments from 02/02/2016.
Omar White, Attorney-In-Fact
2016-02-04